High-resolution melting analysis of the single nucleotide polymorphism hot-spot region in the rpoB gene as an indicator of reduced susceptibility to rifaximin in Clostridium difficile.

Clostridium difficile, a Gram-positive, spore-forming, anaerobic bacterium, is the main causative agent of hospital-acquired diarrhoea worldwide. In addition to metronidazole and vancomycin, rifaximin, a rifamycin derivative, is a promising antibiotic for the treatment of recurring C. difficile infections (CDI). However, exposure of C. difficile to this antibiotic has led to the development of rifaximin-resistance due to point mutations in the β-subunit of the RNA polymerase (rpoB) gene. In the present study, 348 C. difficile strains with known PCR-ribotypes were investigated for respective single nucleotide polymorphisms (SNPs) within the proposed rpoB hot-spot region by using high-resolution melting (HRM) analysis. This method allows the detection of SNPs by comparing the altered melting behaviour of dsDNA with that of wild-type DNA. Discrimination between wild-type and mutant strains was enhanced by creating heteroduplexes by mixing sample DNA with wild-type DNA, leading to characteristic melting curve shapes from samples containing SNPs in the respective rpoB section. In the present study, we were able to identify 16 different rpoB sequence-types (ST) by sequencing analysis of a 325 bp fragment. The 16 PCR STs displayed a total of 24 different SNPs. Fifteen of these 24 SNPs were located within the proposed 151 bp SNP hot-spot region, resulting in 11 different HRM curve profiles (CP). Eleven SNPs (seven of which were within the proposed hot-spot region) led to amino acid substitutions associated with reduced susceptibility to rifaximin and 13 SNPs (eight of which were within the hot-spot region) were synonymous. This investigation clearly demonstrates that HRM analysis of the proposed SNP hot-spot region in the rpoB gene of C. difficile is a fast and cost-effective method for the identification of C. difficile samples with reduced susceptibility to rifaximin and even allows simultaneous SNP subtyping of the respective C. difficile isolates.

[1]  Mark A. Miller,et al.  Divergent Rifamycin Susceptibilities of Clostridium difficile Strains in Canada and Italy and Predictive Accuracy of Rifampin Etest for Rifamycin Resistance , 2011, Journal of Clinical Microbiology.

[2]  Julian Parkhill,et al.  Evidence for several waves of global transmission in the seventh cholera pandemic , 2011, Nature.

[3]  S. Huhulescu,et al.  Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile , 2011, Journal of medical microbiology.

[4]  A. Weintraub,et al.  Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains. , 2010, Anaerobe.

[5]  S. Huhulescu,et al.  Outbreak of Clostridium difficile 027 infection in Vienna, Austria 2008-2009. , 2009, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[6]  Jane W. Marsh,et al.  High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Gerding,et al.  Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile , 2008, Antimicrobial Agents and Chemotherapy.

[8]  S. Huhulescu,et al.  Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007. , 2008, Journal of medical microbiology.

[9]  D. Gerding,et al.  Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Kuijper,et al.  Emergence of Clostridium difficile-associated disease in North America and Europe. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[11]  Elaine Lyon,et al.  Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. , 2004, Clinical chemistry.

[12]  Carl T Wittwer,et al.  High-resolution genotyping by amplicon melting analysis using LCGreen. , 2003, Clinical chemistry.

[13]  Arkady Mustaev,et al.  Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase , 2001, Cell.

[14]  C. Nord,et al.  Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. , 2001, The Journal of antimicrobial chemotherapy.